<DOC>
	<DOCNO>NCT01614990</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy repeat oral administration macimorelin different dos daily 1 week treatment cancer cachexia .</brief_summary>
	<brief_title>Pilot Clinical Trial Repeated Doses Macimorelin Assess Safety Efficacy Patients With Cancer Cachexia</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<criteria>1 . Subjects â‰¥18 year age histological diagnosis incurable cancer ( solid tumor ) , 2 . ECOG performance status 02 , 3 . Presence cancerrelated cachexia define involuntary weight loss least 5 % preillness body weight previous 6 month , 4 . Provide write informed consent prior screen . 1 . Obesity ( body weight &gt; 140 Kg ) ; 2 . Recent active excessive alcohol illicit drug use ; 3 . Severe depression determine investigator ; 4 . Other cause cachexia : Liver disease ( AST ALT &gt; 3x normal level ) ; renal failure ( creatinine &gt; 1.5 mg/dL ) , untreated thyroid disease , class IIIIV CHF , AIDS , cancer diagnose within past 5 year nonmelanoma skin cancer , severe COPD require use home O2 ; 5 . Inability increase food intake ( e.g. , esophageal obstruction , intractable nausea vomit ) ; 6 . Any condition would prevent subject perform research procedure ( e.g . unstable coronary artery disease ) ; 7 . Use growth hormone , megestrol , Marinol , anabolic agent , appetite stimulant ( include corticosteroid dexamethasone time IV chemotherapy administration ) , tube feeding , parenteral nutrition 1 month prior enter study ; 8 . Recent administration ( le 1 week ) highly emetogenic chemotherapy ( Hesketh scale class 45 ) ; subject may otherwise undergoing chemotherapy . 9 . Being female pregnant , breastfeed childbearing potential . ( Note : Lack childbearing potential female patient satisfy : ) post menopausal ; b ) surgically sterile ; c ) practice contraception oral contraceptive , intrauterine device , diaphragm , condom spermicide duration study ; ) sexually inactive . Confirmation patient pregnant establish negative serum hCG pregnancy test time enrollment . 10 . Coadministration drug prolong QT interval ( see appendix XI ) , CYP3A4 inducer ( see appendix XII ) , investigational agent ( washout period five time half life drug prolong QT allow approval prescriber ) . 11 . Conditions would preclude successfully scan subject MRI : Claustrophobia ( would make lie scanner uncomfortable ) ; b. pacemaker , aneurysm clip , neurostimulators , cochlear implant , metal eye , steel worker , implant ; c. History Seizures d. History head injury result loss consciousness &gt; 10 minute .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>